Search Jim Cramer's Mad Money trading recommendations using our exclusive Mad Money Stock Screener and watch Jim Cramer's Mad Money Post Game video exclusively on

NEW YORK ( TheStreet) -- "Stop, look and listen," were Jim Cramer's words to the viewers of his "Mad Money" TV show Friday, as he outlined his game plan for next week's trading.

He said with so many traders selling first, and asking questions later, next week remains a "no trade zone."

Among the stocks Cramer will be paying attention to is Apple ( AAPL), a stock which he owns for his charitable trust, Action Alerts PLUS . Cramer said he wants to hear whether the company can exceed the estimates, or whether earnings will be tempered by an inability to make enough products. He reiterated his $325 price target on Apple, saying the estimates for the company are still too low.

Also in the tech space, Cramer said he'll be watching cloud computing players VMWare ( VMW) and EMC ( EMC), as well as bellwether IBM ( IBM) for a read on the broader tech market.

Also on Cramer's radar, the banks stocks, including CitiGroup ( C), Bank of America ( BAC), another Action Alerts PLUS name, and Wells Fargo ( WFC). Cramer said the mortgage panic is overdone and doesn't take into account these banks' improving fundamentals.

Finally, Cramer said he'll be watching several companies for a read on the global recovery, including Caterpillar ( CAT), Bucyrus ( BUCY) and Freeport-McMoRan ( FCX), along with Action Alerts PLUS stocks Boeing ( BA) and Honeywell ( HON).

With so many stocks reporting, Cramer said he'll barely have time for Chipotle Mexican Grill ( CMG) and Yahoo! ( YHOO), but will be watching those companies as well.

Lucrative Prospects

For "Speculation Friday," Cramer recommended Inspire Pharmaceuticals ( ISPH), the last in his series of biotech companies with blockbuster drug potential.

Cramer said investors have two ways to win with Inspire. First, he said the company is a likely takeover target by Allergan ( AGN). Inspire is already in a close partnership with Allergan for two drugs to treat dry eyes and pink eye. Cramer said it makes sense for Allergan, a much larger company, just to buy all of Inspire, rather than continue licensing it's products.

Even more attractive however is Inspire's pulmonary business and its treatment for cystic fibrosis, which is currently in phase III testing. Cramer said Inspire's treatment is unlike any other, and just received orphan status from the government, meaning it will have no competition. Cramer said the drug, due for approval in the second half of 2011, could be a $300 million to $500 million opportunity.

Cramer said with $106 million in cash on the books, Inspire is not going belly up anytime soon. Cramer said he'd be a buyer of Inspire with so many lucrative prospects.

Going With Teva

Continuing his biotech theme, Cramer honed in on muscular sclerosis, a disease affecting 350,000 people in the U.S., and the companies working towards a cure.

Cramer said MS drugs currently weigh in at $10 billion annually, with estimates upwards of $15 billion over the next 10 years. Cramer said while Biogen Idec ( BIIB) remains a favorite in this space, he'd be a seller of the company, as increased competition is on the horizon.

Cramer explained that new treatments are on the way, including ones that come in pill form, as opposed to an injection, and ones that offer fewer serious side effects. He said the extent to which these new drugs will affect Biogen's business have not been factored into the stock.

But Cramer said he is a fan of Teva Pharmacueticals ( TEVA), the world's largest generic drug maker, which also happens to have a great branded drug business, one quarter of which is dedicated to MS. Teva is also a stock which he also owns for his Action Alerts PLUS portfolio.

Cramer said Teva is the smart, safe way to play MS, as Teva's MS drug will not be affected by new competition. He said the stock took a big hit back in July on patent expiration fears, but those fears were unfounded, as the company's patents remain in good shape through 2014.

Trading at just 10 times earnings, Cramer said Teva is a terrific risk reward, especially given its projected 14% growth rate and healthy drug pipeline.

Broadening Out

In the "Executive Decision" segment, Cramer spoke with Michael Mendes, chairman, president and CEO of Diamond Foods ( DMND), a stock that's up 75% since Cramer recommended it on Dec. 5, 2008.

Mendes explained that his company's recent acquisition of the "Kettle" brand of potato chips has changed Diamond's earnings model and confused some analysts. He said while earnings will be skewed towards the back half of the year, Diamond raised its full-year guidance overall.

Mendes also said that Diamond grew its earnings 52% this past year, and is guiding towards 25% to 30% earnings per share growth next year. He said the company has great brands to drive Diamond forward for many years.

One area of opportunity for the company, according to Mendes, are mass merchandisers and club stores. He said Diamond is making progress in penetrating those channels, where brands must fight harder for limited shelf space.

Mendes also spoke highly of his company's new, all natural tortilla products, marketed under the "Tias" brand. He said Diamond plans to deliver a multi-brand promotion around the Super Bowl to introduce its many exciting new snacks.

Lightning Round

Cramer was bullish on Compass Diversified Holdings ( CODI), Chesapeake Energy ( CHK), Enterprise Products Partners ( EPD) and Cognex ( CGNX).

He was bearish on Netflix ( NFLX) and United States Natural Gas ( UNG).

--Written by Scott Rutt in Washington, D.C.

To contact the writer of this article, click here: Scott Rutt.

To follow the writer on Twitter, go to

To submit a news tip, send an email to:

To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

Want more Cramer? Check out Jim's rules and commandments for investing from his latest book by clicking here.

For more of Cramer's insights during the Lightning Round, click here .
At the time of publication, Cramer was long Apple, Bank of America, Boeing, Honeywell, Teva Pharmaceuticals.

Jim Cramer, host of the CNBC television program "Mad Money," is a Markets Commentator for, Inc., and CNBC, and a director and co-founder of All opinions expressed by Mr. Cramer on "Mad Money" are his own and do not reflect the opinions of or its affiliates, or CNBC, NBC UNIVERSAL or their parent company or affiliates. Mr. Cramer's opinions are based upon information he considers to be reliable, but neither, nor CNBC, nor either of their affiliates and/or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such. Mr. Cramer's statements are based on his opinions at the time statements are made, and are subject to change without notice. No part of Mr. Cramer's compensation from CNBC or is related to the specific opinions expressed by him on "Mad Money."

None of the information contained in "Mad Money" constitutes a recommendation by Mr. Cramer, or CNBC that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the program. Mr. Cramer's past results are not necessarily indicative of future performance. Neither Mr. Cramer, nor, nor CNBC guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the program. The strategy or investments discussed may fluctuate in price or value and you may get back less than you invested. Before acting on any information contained in the program, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.

Some of the stocks mentioned by Mr. Cramer on "Mad Money" are held in Mr. Cramer's Action Alerts PLUS Portfolio. When that is the case, appropriate disclosure is made on the program and in the "Mad Money" recap available on The Action Alerts PLUS Portfolio contains all of Mr. Cramer's personal investments in publicly-traded equity securities only, and does not include any mutual fund holdings or other institutionally managed assets, private equity investments, or his holdings in, Inc. Since March 2005, the Action Alerts PLUS Portfolio has been held by a Trust, the realized profits from which have been pledged to charity. Mr. Cramer retains full investment discretion with respect to all securities contained in the Trust. Mr. Cramer is subject to certain trading restrictions, and must hold all securities in the Action Alerts PLUS Portfolio for at least one month, and is not permitted to buy or sell any security he has spoken about on television or on his radio program for five days following the broadcast.

If you liked this article you might like

Good Biotech Stocks for a Bear Market

Good Biotech Stocks for a Bear Market

Merck to Buy Inspire for $430 Million

Merck to Buy Inspire for $430 Million

Inspire Pharma Plunges After Drug Trial Failure

Inspire Pharma Plunges After Drug Trial Failure

Biotech Winners & Losers: Geron, Jazz Pharma

Biotech Winners & Losers: Geron, Jazz Pharma